How should I manage a patient with severe renal impairment (BUN 51 mg/dL, eGFR 18 mL/min/1.73 m², creatinine 2.87 mg/dL) and hyperkalemia (potassium 5.7 mmol/L) with anemia (low RBC, hemoglobin, hematocrit)?

Management of Severe CKD with Hyperkalemia and Anemia

This patient with Stage 4-5 CKD (eGFR 18) and moderate hyperkalemia (K+ 5.7) requires urgent nephrology referral for dialysis planning, immediate hyperkalemia management, and anemia workup—dialysis initiation should be considered given the constellation of uremia, electrolyte abnormalities, and anemia. 1

Immediate Priorities

1. Assess for Dialysis Indications

This patient meets criteria for urgent nephrology evaluation and likely dialysis initiation based on: 1

• eGFR 18 mL/min/1.73 m² places them in Stage 4-5 CKD, approaching the threshold where dialysis planning should occur (typically eGFR <15-20) 1
• BUN 51 mg/dL suggests uremic symptoms may be present or imminent 1
• Moderate hyperkalemia (K+ 5.7 mmol/L) that is "medically resistant" to conservative management is an absolute indication for dialysis 1
• Anemia with low RBC/Hgb/Hct suggests progressive CKD complications requiring intervention 2, 3

Key clinical assessment needed: Evaluate for uremic symptoms (nausea, anorexia, altered mental status, pericarditis, pruritus), volume overload, or progressive nutritional deterioration—any of these mandate dialysis initiation even at eGFR >10. 1

2. Hyperkalemia Management

Classification: K+ 5.7 mmol/L represents moderate hyperkalemia (5.5-6.0 mEq/L). 1

Immediate steps:

• Obtain ECG immediately to assess for peaked T waves, flattened P waves, prolonged PR interval, or widened QRS—these indicate cardiac membrane instability requiring emergent treatment 4
• Rule out pseudohyperkalemia: Repeat potassium measurement with proper technique (no fist clenching, minimal tourniquet time) or obtain arterial sample if hemolysis suspected 1, 5

Acute treatment (if ECG changes present or K+ rising):

• Calcium gluconate or calcium chloride for cardiac membrane stabilization 6
• Insulin with glucose (10 units regular insulin + 25g dextrose IV) to shift potassium intracellularly 6, 4
• Loop diuretics (if urine output preserved) to enhance renal excretion 6
• Consider sodium bicarbonate if metabolic acidosis present 6

Subacute/chronic management:

• Review and adjust medications: Identify potassium-retaining drugs (ACE inhibitors, ARBs, spironolactone, NSAIDs, beta-blockers, trimethoprim) 1, 5
• Critical decision point: Do NOT automatically discontinue RAAS inhibitors—these reduce mortality in CKD and cardiovascular disease. Instead, consider dose reduction first or add potassium binders to maintain therapy 1, 6
• Potassium binders: Patiromer or sodium zirconium cyclosilicate for chronic management; sodium polystyrene sulfonate for acute use 6, 7
• Dietary restriction: Limit potassium intake to <3g/day (avoid bananas, melons, orange juice, potatoes, tomatoes, salt substitutes) 5, 6

Common pitfall: Up to 75% of hyperkalemia patients are taking potassium-increasing drugs, particularly RAAS inhibitors and spironolactone—these are often inappropriately discontinued rather than dose-adjusted despite mortality benefits. 1, 8

3. Anemia Evaluation and Management

Workup required: 2, 3

• Complete blood count with indices
• Iron studies (serum iron, TIBC, ferritin, transferrin saturation)
• Reticulocyte count
• Rule out other causes: B12, folate, hemolysis markers, occult bleeding

Treatment approach:

• Iron deficiency: Most common cause in CKD, especially with eGFR <30. Intravenous iron is preferred over oral in dialysis patients and those with eGFR <30 due to poor absorption and hepcidin elevation 2, 3, 9
• Erythropoiesis-stimulating agents (ESAs): Recommended as first-line therapy for anemia of CKD after iron repletion. Target hemoglobin individualized but generally 10-11.5 g/dL to avoid cardiovascular risks 2, 3, 9
• Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs): Newer oral agents, but ESAs remain preferred first-line due to more established safety profile 2, 9

Monitoring: More frequent assessment needed in advanced CKD—check hemoglobin, iron studies, and potassium every 1-3 months minimum 3, 10

Nephrology Referral Urgency

Refer immediately (within 24-48 hours) for: 1

• Dialysis access planning (arteriovenous fistula creation ideally occurs when eGFR 15-20, requiring 3-6 months to mature)
• Assessment for preemptive kidney transplantation evaluation (indicated when eGFR <20 or 2-year KRT risk >40%)
• Comprehensive conservative management discussion if patient declines dialysis

Risk stratification: This patient has multiple high-risk features for adverse outcomes: 5

• Advanced CKD (eGFR 18)
• Hyperkalemia (occurs in up to 73% of advanced CKD patients)
• Anemia (universal in Stage 4-5 CKD)
• Likely on RAAS inhibitors (present in 50% of CKD patients with recurrent hyperkalemia)

Monitoring Plan

Until nephrology evaluation:

• Recheck potassium within 24-48 hours after any intervention 6
• Weekly potassium monitoring if stable on medical management 7
• Avoid nephrotoxins (NSAIDs, contrast, aminoglycosides)
• Monitor for uremic symptoms daily (nausea, confusion, pericardial rub, asterixis)

Critical threshold: If potassium rises to ≥6.0 mEq/L (severe hyperkalemia) or ECG changes develop, this becomes a medical emergency requiring hospitalization and likely urgent dialysis. 1, 4